Showing 683 results
-
Media Release /- BRAF mutation status is an important factor when choosing a first-line therapy for patients with stage III and stage IV melanoma- The Know Now Testing Program covers cost of this genetic mutation…
-
Media Release /
-
Media Release /- Five-year Tafinlar + Mekinist survival data presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting and published simultaneously in The New England Journal of Medicine-…
-
Media Release /
-
Media Release /- Primary analysis of investigational capmatinib (INC280) in the GEOMETRY mono-1 study demonstrates promising efficacy in patients with locally advanced or metastatic non-small cell lung cancer (…
-
Media Release /
-
Media Release /- One-time treatment with Zolgensma (onasemnogene abeparvovec-xioi) is designed to replace lifetime of chronic therapy for all pediatric patients with SMA- Annualized cost of Zolgensma is USD 425,000…
-
Media Release /- SMA is a rare genetic disease that leads to progressive muscle weakness, paralysis and, when left untreated in its most severe form, permanent ventilation or death for most patients by age 2[1,2]-…
-
Media Release /
-
Media Release /
